













CRUK CENTRE FOR DRUG DEVELOPMENT








BIOLOGICAL THERAPIES

AGENT/TRIAL	TARGET/ TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	DEVELOPMENT STAGE					
					PROJECT INITIATION	EXPLORAT- ORY	PRE- CLINICAL	TRIAL SET UP	PHASE I	PHASE II
CY101	Peptide β-catenin, WNT	 cytovation NORWEGIAN CANCER SOCIETY	Adenocortical carcinoma	First in class→					
KJ103	Antibody TROP2	 木曾 印路 Kisoji	Solid	First in class→					
NVG222 solid	BITE ROR1, CD3	 NOVALGEN	Solid	First in indication→					
NVG222 haematological	BITE ROR1, CD3	 NOVALGEN	Lymphoma	First in human→					
ALETA001	Protein CD19, CD20	 ALETA BIO THERAPEUTICS	Lymphoma	First in class→					
HMBD001	Antibody Her3	 Hummingbird Bioscience	Solid, prostate	First in human→					
VTP600 (MAGE)	Vaccine MAGE3, NY-ESO-1	 BARINTHUS BIO THERAPEUTICS	Lung	First in human (closed)→					
UCB4594	Antibody HLA-G1	 ucb	Solid, renal	First in human→					
DETERMINE - Atezolizumab - Trastuzumab/ Pertuzumab	Antibodies PDL1 HER2	 MANCHESTER 1927 The University of Manchester  Roche	Rare adult, paediatric & TYA cancers	Phase II→					
				Phase II combination→					
Ginisortamab (UCB6114)	Antibody Gremlin1	 ucb  NORWEGIAN CANCER SOCIETY	Pancreatic	First in class Phase II→					

There are two other undisclosed programmes in development: a small molecules combination and a protein degrader.

CRUK CENTRE FOR DRUG DEVELOPMENT

SMALL MOLECULE THERAPIES

AGENT/TRIAL	TARGET/ TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	DEVELOPMENT STAGE					
					PROJECT INITIATION	EXPLORAT- ORY	PRE- CLINICAL	TRIAL SET UP	PHASE I	PHASE II
BT1718	MT1-MMP		Solid, lung	First in class (closed)						
HTL0039732	EP4		Solid, colorectal, prostate, gastric, oesophageal, renal	First in human						
LY3143921	Cdc7		Solid, colorectal, ovarian, lung	First in human (closed)						
TT702 (CURATE)	adenosine A _{2B} R		Solid	First in human						
DETERMINE - Alectinib - Capmatinib - Entrectinib - Vemurafenib/ Cobimetinib	ALK, TK1 cMET, HGFR ROS1, TRK, ALK BRAF, MAP, MEK	  	Rare adult, paediatric & TYA cancers	Phase II Phase II Phase II Phase II combination						

There are two other undisclosed programmes in development: a small molecules combination and a protein degrader.